

Neuronal survival in epilepsy: to die or not to die?

Epilepsy is a chronic neurological condition characterized by recurrent and unprovoked seizures, affecting 1% of people worldwide. Historically, epilepsy was called the “sacred disease” because people thought that epileptic seizures were a form of attack by demons, and that the visions epileptics experienced were sent by the Gods (Riggs and Riggs 2005). Epilepsy can have many causes, including brain injury, poisoning, head trauma, or stroke; and these factors are not restricted to any age group, sex, or race and neither is epilepsy. Moreover, genetic factors are known to play a major role in many epileptic forms, accounting for 40% of all epilepsies (Annegers *et al* 1996). A small proportion of epilepsy subtypes are inherited as single-gene (‘Mendelian’) traits. In the remaining cases, the etiology is complex, arising from the contribution of multiple genetic and non-genetic factors. The rapidly expanding and exciting discoveries in epilepsy genetics in the last ten years are the key for unraveling the basic mechanisms of seizure disorders and predicting what lies ahead for patients. Currently, more than twenty five genes have been identified to cause epilepsy in human, primarily the monogenic forms (tables 1 and 2). However, the genetic architecture of some of these Mendelian forms can explain the complexities of the common epilepsies (Delgado-Escueta *et al* 2003). Beyond genetics, we are finally looking at what these mutations do in cellular, animal and human models by developing sophisticated *in vitro* and *in vivo* functional validation assays. Such approaches link epilepsy genes to both anti- and pro-apoptotic functions. This note introduces the cellular functions of a few epilepsy genes and discusses a unifying model for epileptogenesis.

Progressive myoclonus epilepsy (PME) is a subsyndrome of epilepsies involving the central nervous system (Delgado-Escueta *et al* 2001). The PME include: Unverricht–Lundborg disease (ULD), Lafora disease (LD), myoclonic epilepsy with ragged-red fibre syndrome (MERRF), the neuronal ceroid lipofuscinoses (NCL), dentatorubropallidolusian atrophy (DRPLA) and sialadosis (table 1). A hallmark of PME is the progressive neurologic deterioration and neurodegeneration (Delgado-Escueta *et al* 2001). While the genetic cause of each of these PMEs is identified, defects in at least four genes are proven to be directly linked to neuronal cell death. In ULD, the causative gene, *CSTB*, encodes a cysteine proteases inhibitor named as cystatin B (Pennacchio *et al* 1996). Mice deficient for cystatin B, produced by targeted disruption of the mouse *Cstb* gene, display a phenotype similar to the human disease, with progressive ataxia and myoclonic seizures. The mice show neuronal atrophy, apoptosis and gliosis as well as increased expression of apoptosis and glial activation genes (Pennacchio *et al* 1998; Lieuallen *et al* 2001). Under normal circumstances, the action of caspases, a family of cysteine proteases involved in the initiation of apoptosis, is directly inhibited by cystatin B. In the absence of functional cystatin B, however, caspases would trigger the apoptotic process leading to cell death (Delgado-Escueta *et al* 2001). The second player in PME involved in neuronal cell death is the *EPM2A* gene encoded laforin phosphatase, the protein defective in LD (Ganesh *et al* 2000). Targeted disruption of *Epm2a* gene in mice led to the development of widespread neurodegeneration, inclusion bodies, ataxia, and myoclonus epilepsy, the defining phenotypes of LD in humans (Ganesh *et al* 2002). Notably, dying neurons in the mutant mice exhibited swelling in the endoplasmic reticulum, Golgi networks and mitochondria in the absence of apoptotic bodies or fragmentation of DNA, suggesting the involvement of a novel form of cell-death in LD and that laforin is critical for neuronal survival (Ganesh *et al* 2002). The third player is the product of the gene involved in juvenile form of NCL, also known as Batten disease (BD) (International Batten Disease Consortium 1995) (table 1). BD is associated with accelerated apoptotic death of photoreceptors and neurons resulting from defects in the *CLN3* gene. Intriguingly, *CLN3* protein is anti-apoptotic when overexpressed in neuronal precursor cells and therefore has been suggested as a novel molecular target for cancer drug

discovery (Dhar *et al* 2002; Rylova *et al* 2002). And the fourth player directly involved in neuronal survival is atrophin-1 involved in DRPLA. While loss-of-function mutations result in the development of UCL, LD and BD, a gain-of-function mutation leads to the development of DRPLA; the expansions of a CAG trinucleotide repeat encoding polyglutamine in the atrophin-1 gene (Nagafuchi *et al* 1994). Both patients and DRPLA transgenic mice have nuclear accumulation of polyglutamine containing atrophin-1 and the cleavage of atrophin-1 by caspases enhances the cytotoxicity leading to cell death (Sato *et al* 1999; Nucifora *et al* 2003). Thus, combined degeneration of the dentatorubral tract and pallidolusian system is thought to underlie the neuropathology in DRPLA (Delgado-Escueta *et al* 2001).

Contrary to the pathological features seen in PMEs, the epileptic forms that lack 'detectable' brain lesions and/or other neurological defects are called as idiopathic epilepsies (IE). The latter ones are presumed to be genetic and are generally age-dependent. Thus, the most common forms of IEs are epilepsies of infancy, childhood, and adolescence, namely febrile convulsions, juvenile myoclonus epilepsy and childhood absence epilepsy (Delgado-Escueta *et al* 2003; Mulley *et al* 2003). Progress has also been made with respect to identifying genes involved in several IEs – although with limited success. As suspected on the basis of physiological evidence, a majority of these genes encode subunits of voltage-gated or neurotransmitter-gated ion channels, leading to the concept that a majority of the IEs are 'channelopathies', underscoring abnormal channel functions in neuronal excitability and that they provide important targets for anticonvulsant drugs (Mulley *et al* 2003; Kass 2005) (table 2). Nonetheless, success with finding mutations in ion channels genes has not been encouraging as only a very few families screened showed defective genes (less than 2%; table 2) as against hundreds of families for PMEs. These observations provide further evidence for the high level of genetic heterogeneity associated with IEs (table 2). This would as well mean that the Mendelian mutations

Table 1. Genes implicated in progressive myoclonus epilepsies.

Disease	Inheritance*	Chromosomal locus	Gene	Protein	Function	MIM ID [†]
Unverricht-Lundborg disease (ULD)	AR	21q22.3	<i>CSTB</i>	Cystatin B	Lysosomal cysteine protease inhibitor	254800
Lafora's disease (LD)	AR	6q24	<i>EPM2A</i>	Laforin	Dual specificity protein phosphatase	254780
		6p22	<i>NHLRC1</i> (<i>EPM2B</i>)	Malin	E3 ubiquitin liage	
Myoclonic epilepsy with ragged red fibres (MERRF)	M	Mitochondrial DNA	<i>MTTK</i>	–	Encodes tRNA for lysine amino acid residue	545000
Neuronal ceroid lipofuscinoses (NCLs)						
Classic late infantile NCL (type 2)	AR	11p15.5	<i>TPP1</i> (<i>CLN2</i>)	Tripeptidyl peptidase 1	Lysosomal serine protease	204500
Juvenile NCL (type 3); Batten disease	AR	16p12.1	<i>CLN3</i>	CLN3 protein	Membrane protein with an anti apoptotic function	607042
Late infantile Finnish variant NCL (type 5)	AR	13q21.1-q32	<i>CLN5</i>	CLN5 protein	Lysosomal protein with unknown functions	608102
Sialidoses	AR	6p21.3	<i>NEU1</i>	Sialidase 1	Removal of sialic acid from glycolipids and glycoproteins	608272
Dentatorubral-pallidolusian atrophy (DRPLA)	AD	12p13-31	<i>DRPLA</i> (<i>ATNI</i>)	Atrophin 1	Phosphoprotein with unknown functions	607462

*AR, autosomal recessive; AD, autosomal dominant; M, maternal.

[†]Further details on the gene, mutations, and disease can be obtained from the OMIM link (<http://www.ncbi.nlm.nih.gov/omim>), using the MIM number provided.

associated with IEs are perhaps unique to specific families because mutant alleles are rare even in the same ethnic population they were discovered (Delgado-Escueta *et al* 2003).

One of the few exceptions to the notion of 'channelopathies' is the recent discovery of *EFHC1* gene, implicated in juvenile myoclonus epilepsy (JME) (Suzuki *et al* 2004). Mutations in *EFHC1* were identified in Mexican families with JME and all mutations were single amino acid substitutions. The gene encodes a 640-amino acid long protein, named myoclonin, and contains an EF hand calcium-binding motif. In mice, myoclonin is localized on neuronal dendrites and soma, but were not

Table 2. Genes implicated in idiopathic epilepsies.

Gene	Chromosome locus	Type of epilepsy [†]	Number of families with mutations	MIM ID*	Major function
Sodium channel genes					
<i>SCN2A</i>	2q23-q24.3	BFNIS	8	607745	Generation and propagation of action potentials in striated muscle and neuronal tissues
		GEFS	1	604233	
<i>SCN1B</i>	19q13.1	GEFS	3	604233	
<i>SCN1A</i>	2q24	GEFS SMEI	10 54	604233 607208	
Calcium channel genes					
<i>CACNB4</i>	2q22-23	IGE	1	600669	Mediate the influx of calcium ions into the cell upon membrane polarization
		JME	1	606904	
<i>CACNA1A</i>	19p13	EA	2	108500	
Nicotinic acetylcholine receptor genes					
<i>CHRNA4</i>	20q13.2-q13.3	ADNFLE	4	6000513	Mediate fast transmission at synapses
<i>CHRN2</i>	1p21	ADNFLE	2	605375	
Potassium channel genes					
<i>KCNQ2</i>	20q13.3	BFNC/ myokymia	7	121200	Regulate neuronal excitability
			1	606437	
<i>KCNQ3</i>	8q24	BFNC	1	121201	
<i>KCNA1</i>	12p13	EA	1	160120	
Gamma-amino butyric acid (GABA) receptor genes					
<i>GABRA1</i>	5q34	JME	1	606904	Increases the permeability to chloride ions, leading to hyperpolarization of the neuron or inhibition
<i>GABRG2</i>	5q31.1-q33.1	GEFS	2	604233	
		CAE	2	607681	
Chloride channel genes					
<i>CLCN2</i>	3q26	CAE	1	607682	Regulates the electric excitability of plasma membrane
	3q26-qter	EGMA	1	607628	
Non ion channel genes					
<i>LGII</i>	10q24	ADPEAF	10	600512	Transmembrane protein involved in signal transduction pathway
<i>EFHC1</i>	6p12-p11	JME	6	254770	Enhances calcium ion influx
<i>BRD2</i>	6p21.3	JME	CC	608816	Mitogen-activated kinase
<i>ME2</i>	18q21	IGE	CC	600669	NAD-dependent malic enzyme localized in mitochondrial

[†]BFNIS, benign familial neonatal and infantile seizures; GEFS, generalized epilepsy with febrile seizures; SMEI, severe myoclonic epilepsy in infancy; IGE, idiopathic generalized epilepsy; JME, juvenile myoclonus epilepsy; EA, episodic ataxia; CAE, childhood absence epilepsy; ADPEAF, autosomal dominant partial epilepsy with auditory features; ADNFLE, autosomal dominant nocturnal frontal lobe epilepsy; BFNC, benign familial neonatal convulsions; EGMA, epilepsy with grand mal upon awakening; CC, case-control analysis.

*Further details on the gene, mutations, and disease can be obtained from the OMIM link (<http://www.ncbi.nlm.nih.gov/omim>), using the MIM number provided.

observed at axons. Curiously, expression of wild type myoclonin in the same system resulted in shorter neuritic processes with fewer branches, subsequently leading to cell death through the apoptotic process. Expression of *EFHC1* mutants, on the other hand, substantially reduced the cell-death effect, suggesting that wild-type myoclonin is involved in triggering apoptosis and that the JME mutations might disrupt this complex process of programmed cell death. Intriguingly, usage of calcium channel blockers increased the survival rate of neurons expressing wild-type myoclonin. The induction of apoptosis should therefore be through the activation of calcium channels. Patch-clamp experiments did demonstrate that expression of myoclonin increased the activity of $Ca_v2.3$ voltage-gated calcium channels. Thus, apoptosis is mostly likely to be triggered by the increased calcium influx as a result of myoclonin mediated $Ca_v2.3$ activation. Indeed, the immunosignals of the myoclonin and $Ca_v2.3$ proteins show overlapping localization patterns in neurons and these two proteins do interact physically. Taken together, this study reveals a molecular basis for JME and suggests that mutations in *EFHC1* might abolish the apoptotic process in the brain by failing to activate the voltage gated calcium channels (Suzuki *et al* 2004).

This conclusion brings us to an intriguing question as to how a failure to initiate the programmed cell death (PCD) would lead to the development epileptic symptoms. One answer to this question lies in the developmental mechanisms. PCD is known to be an important event in the normal development of the mammalian nervous system, where it regulates the final number of neuronal and glial cell populations. During embryonic development up to 70% of the neural cells are eliminated through PCD (De Zio *et al* 2005). This elimination is very much required for the morphogenetic changes occurring in the developing brain, for example the neural tube closure. The delicate balance between proliferation and death of these cells thus underlie the critical developmental process of the nervous system. The *EFHC1* gene product myoclonin could be one of such critical players, and mutations therein might cause the unwanted neurons to survive, resulting in an increased density of a subset of neurons in the JME patients. A rigorous quantitative magnetic resonance imaging analysis indeed detect an increase in cortical gray matter of JME patients, suggesting a pathological mechanism resulting in subtle cerebral structural abnormality (Woermann *et al* 1999). These changes may be associated with abnormalities in functional connectivity leading to the production of hyperexcitable circuits and epileptic seizures. It is of interest to note that myoclonin is not the only player that is involved in both epileptogenesis and pro-apoptotic function. *BRD2* gene showed a significant association for a genetic polymorphism and susceptibility for developing JME (Pal *et al* 2003). The *BRD2* protein is a nuclear transcriptional regulator that is found in the human brain and plays an important function in the development of the central nervous system (Guo *et al* 2000; Crowley *et al* 2004). *BRD2* may also be a pro-apoptotic protein because of its proposed function as a mitogen-activated protein kinase (MAPK). MAPK constitute one of the critical components of a signal transduction pathway that regulates a variety of cellular process including cell growth and apoptosis (Liou *et al* 2003). *LGII* protein is yet another factor that modulates the MAPK pathway (Kunapuli *et al* 2004). *LGII* was first identified as a candidate tumour suppressor gene for glioma (Chernova *et al* 1998). Surprisingly, mutations in *LGII* were also associated with an IE subtype, the autosomal dominant lateral temporal lobe epilepsy (Kalachikov *et al* 2002).

The recent advances in the understanding of cellular functions of epilepsy genes, such as *CSTB*, *EPM2A*, *CLN3*, *EFHC1*, and *LGII*, unravel several hitherto unknown pathways in the genesis of epilepsy. They also identify the molecular players that control the development and maintenance of normal brain structure and functions, which are regulated by the cell survival as well as cell-death pathways. Whereas an extensive neuronal degeneration is associated with the PME, slight changes in neuronal density might underlie the pathophysiology of IEs. Thus either an increase or decrease in the neuronal population would results in disorganized neuronal connectivity leading to epileptic seizures. These studies propose structural changes in the brain as the underlying cause in both PME and IE, and might prove useful to future medicine and surgery.

Acknowledgements

Financial support from the Department of Science and Technology and Council of Scientific and Industrial Research, New Delhi is gratefully acknowledged.

References

- Annegers J F, Rocca W A and Hauser W A 1996 Causes of epilepsy: contributions of the Rochester epidemiology project; *Mayo Clin. Proc.* **71** 570–575
- Chernova O B, Somerville R P and Cowell J K 1998 A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors; *Oncogene* **17** 2873–2881
- Crowley T, Brunori M, Rhee K, Wang X and Wolgemuth D J 2004 Change in nuclear-cytoplasmic localization of a double-bromodomain protein during proliferation and differentiation of mouse spinal cord and dorsal root ganglia; *Brain Res. Dev. Brain Res.* **149** 93–101
- De Zio D, Giunta L, Corvaro M, Ferraro E and Cecconi F 2005 Expanding roles of programmed cell death in mammalian neurodevelopment; *Semin. Cell. Dev. Biol.* **16** 281–294
- Delgado-Escueta A V, Perez-Gosiengfiao K B, Bai D, Bailey J, Medina M T, Morita R, Suzuki T, Ganesh S, Sugimoto T, Yamakawa K, Ochoa A, Jara-Prado A, Rasmussen A, Ramos-Peek J, Cordova S, Rubio-Donnadieu F and Alonso M E 2003 Recent developments in the quest for myoclonic epilepsy genes; *Epilepsia* **11** 13–26
- Delgado-Escueta AV, Ganesh S and Yamakawa K 2001 Advances in the genetics of progressive myoclonus epilepsy; *Am. J. Med. Genet.* **106** 129–138
- Dhar S, Bitting R L, Rylova S N, Jansen P J, Lockhart E, Koeberl D D, Amalfitano A and Boustany R M F 2002 Lupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons; *Ann. Neuro.* **51** 448–466
- Ganesh S, Agarwala K L, Ueda K, Akagi T, Shoda K, Usui T, Hashikawa T, Osada H, Delgado-Escueta A V and Yamakawa K 2000 Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes; *Hum. Mol. Genet.* **9** 2251–2261
- Ganesh S, Delgado-Escueta A V, Sakamoto T, Avila M R, Machado-Salas J, Hoshii Y, Akagi T, Gomi H, Suzuki T, Amano K, Agarwala K L, Hasegawa Y, Bai D S, Ishihara T, Hashikawa T, Itoharu S, Cornford E M, Niki H and Yamakawa K 2002 Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice; *Hum. Mol. Genet.* **11** 1251–1262
- Guo N, Faller D V and Denis G V 2000 Activation-induced nuclear translocation of RING3; *J. Cell Sci.* **113** 3085–3091
- International Batten Disease Consortium 1995 Isolation of a novel gene underlying Batten disease, CLN3; *Cell* **82** 949–957
- Kalachikov S, Evgrafov O, Ross B, Winawer M, Barker-Cummings C, Martinelli Boneschi F, Choi C, Morozov P, Das K, Teplitskaya E, Yu A, Cayanis E, Penchaszadeh G, Kottmann A H, Pedley T A, Hauser W A, Ottman R and Gilliam T C 2002 Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features; *Nat. Genet.* **30** 335–341
- Kass R S 2005 The channelopathies: novel insights into molecular and genetic mechanisms of human disease; *J. Clin. Invest.* **115** 1986–1989
- Kunapuli P, Kasyapa C S, Hawthorn L and Cowell J K 2004 LGI1, a putative tumour metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway; *J. Biol. Chem.* **279** 23151–23157
- Lieuallen K, Pennacchio L A, Park M, Myers R M and Lennon G G 2001 Cystatin B-deficient mice have increased expression of apoptosis and glial activation genes; *Hum. Mol. Genet.* **10** 1867–1871
- Liou A K, Clark R S, Henshall D C, Yin X M and Chen J 2003 To die or not to die for neurons in ischemia, traumatic brain injury and epilepsy: a review on the stress-activated signaling pathways and apoptotic pathways; *Prog. Neurobiol.* **69** 103–142
- Mulley J C, Scheffer I E, Petrou S and Berkovic S F 2003 Channelopathies as a genetic cause of epilepsy; *Curr. Opin. Neurol.* **16** 171–176
- Nagafuchi S, Yanagisawa H, Ohsaki E, Shirayama T, Tadokoro K, Inoue T and Yamada M 1994 Structure and expression of the gene responsible for the triplet repeat disorder, dentatorubral and pallidoluyian atrophy (DRPLA); *Nat. Genet.* **8** 177–182
- Nucifora F C Jr, Ellerby L M, Wellington C L, Wood J D, Herring W J, Sawa A, Hayden M R, Dawson V L, Dawson T M and Ross C A 2003 Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity; *J. Biol. Chem.* **278** 13047–13055
- Pal D K, Evgrafov O V, Tabares P, Zhang F, Durner M and Greenberg D A 2003 BRD2 (RING3) is a probable major susceptibility gene for common juvenile myoclonic epilepsy; *Am. J. Hum. Genet.* **73** 261–270
- Pennacchio L A, Bouley D M, Higgins K M, Scott M P, Noebels J L and Myers R M 1998 Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice; *Nat. Genet.* **20** 251–258
- Pennacchio L A, Lehesjoki A E, Stone N E, Willour V L, Virtaneva K, Miao J, D'Amato E, Ramirez L, Faham M, Koskineniemi M, Warrington J A, Norio R, de la Chapelle A, Cox D R and Myers R M 1996 Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1); *Science* **271** 1731–1734
- Riggs A J and Riggs J E 2005 Epilepsy's role in the historical differentiation of religion, magic and science; *Epilepsia* **46** 452–453
- Rylova S N, Amalfitano A, Persaud-Sawin D A, Guo W X, Chang J, Jansen P J, Proia A D and Boustany R M 2002 The CLN3 gene is a novel molecular target for cancer drug discovery; *Cancer Res.* **62** 801–808

- Sato A, Shimohata T, Koide R, Takano H, Sato T, Oyake M, Igarashi S, Tanaka K, Inuzuka T, Nawa H and Tsuji S 1999 Adenovirus-mediated expression of mutant DRPLA proteins with expanded polyglutamine stretches in neuronally differentiated PC12 cells. Preferential intranuclear aggregate formation and apoptosis; *Hum. Mol. Genet.* **8** 997–1006
- Suzuki T, Delgado-Escueta A V, Aguan K, Alonso M E, Shi J, Hara Y, Nishida M, Numata T, Medina M T, Takeuchi T, Morita R, Bai D, Ganesh S, Sugimoto Y, Inazawa J, Bailey J N, Ochoa A, Jara-Prado A, Rasmussen A, Ramos-Peek J, Cordova S, Rubio-Donnadieu F, Inoue Y, Osawa M, Kaneko S, Oguni H, Mori Y and Yamakawa K 2004 Mutations in EFHC1 cause juvenile myoclonic epilepsy; *Nat. Genet.* **36** 842–849
- Woermann F G, Free S L, Koepp M J, Sisodiya S M and Duncan J S 1999 Abnormal cerebral structure in juvenile myoclonic epilepsy demonstrated with voxel-based analysis of MRI; *Brain* **122** 2101–2108

SUBRAMANIAM GANESH*

SHWETA SINGH

*Department of Biological Sciences and Bioengineering,
Indian Institute of Technology,
Kanpur 208 016, India
(Email, sganesh@iitk.ac.in)

ePublication: 23 November 2005